180 Life Sciences Corp. (ATNF)
NASDAQ: ATNF · Real-Time Price · USD
2.210
-0.600 (-21.35%)
At close: Jul 22, 2025, 4:00 PM
2.360
+0.150 (6.79%)
After-hours: Jul 22, 2025, 7:54 PM EDT
Company Description
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States.
The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain.
180 Life Sciences Corp. is headquartered in Palo Alto, California.
180 Life Sciences Corp.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Lloyd Jordan |
Contact Details
Address: Building 4, Suite 200 Palo Alto, California 94306 United States | |
| Phone | 650 285 2387 |
| Website | 180lifesciences.com |
Stock Details
| Ticker Symbol | ATNF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | 68236V104 |
| ISIN Number | US68236V3024 |
| Employer ID | 81-3832378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lloyd Blair Jordan L.L.B., M.B.A. | Chief Executive Officer and Director |
| Sir Marc Feldman Ph.D. | Co-Founder |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder and Director |
| Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder and Chairman of Clinical Advisory Board |
| Eric R. Van Lent | CAO, Principal Accounting and Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 22, 2025 | SCHEDULE 13G/A | Filing |
| Jul 14, 2025 | 8-K | Current Report |
| Jul 7, 2025 | ARS | Filing |
| Jul 7, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 2, 2025 | SCHEDULE 13D/A | Filing |
| Jul 1, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 8-K/A | [Amend] Current report |
| Jun 26, 2025 | EFFECT | Notice of Effectiveness |
| Jun 26, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 25, 2025 | 8-K | Current Report |